Diabetes Mellitus and diabetic ketoacidosis associated with pembrolizumab
| Autor: | Karla Lauš, Hrvoje Centner, Ema Schönberger, Silvija Canecki-Varžić |
|---|---|
| Jazyk: | English<br />Croatian |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Liječnički vjesnik, Vol 145, Iss Supp 2, Pp 62-62 (2023) |
| Druh dokumentu: | article |
| ISSN: | 0024-3477 1849-2177 |
| DOI: | 10.26800/LV-145-supl2-CR31 |
| Popis: | Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus (DM) and is characterized by hyperglycemia, hyperketonemia and metabolic acidosis. With the increasing use of immune checkpoint inhibitors (ICIs), such as pembrolizumab in cancer therapy, it’s important tounderstand immune-related adverse events that comes with it. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|